AKT1 and thyroid gland carcinoma: In thyroid cancer, in particular BRAF-mutated PTC, activation of both intrinsic (RAF-MEK-ERK) and extrinsic (PI3K-AKT-mTOR) pathways have been proposed as mechanisms of resistance to BRAF inhibitors.